NCT00078000已完成2 期
A Phase 2 Study Of The Efficacy And Safety Of SU011248 In Patients With Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 64
- 试验地点
- 11
- 主要终点
- Anti-tumor efficacy
研究概览
简要总结
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Anthracycline and taxane-refractory or intolerant metastatic breast cancer
排除标准
- •Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.
结局指标
主要结局
Anti-tumor efficacy
次要结局
- Tumor control survival safety pharmacokinetics
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Treatment With SU11248 in Patients With Neuroendocrine TumorsNeuroendocrine TumorsNCT00056693Pfizer107
已完成
2 期
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.Colorectal NeoplasmsNCT00077987Pfizer84
已完成
2 期
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00092001Pfizer111
终止
2 期
Efficacy of SU 011248 in Head And Neck CarcinomaRecurrent DiseaseSquamous Cell Head and Neck CarcinomaPalliative TreatmentNCT00408252Cliniques universitaires Saint-Luc- Université Catholique de Louvain54
已完成
2 期
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesNon-Small Cell Lung CancerNCT00372775Pfizer66